Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

This study has been terminated.
Medical Research Networx LLC
Information provided by (Responsible Party):
Fujirebio Diagnostics, Inc. Identifier:
First received: May 2, 2012
Last updated: July 12, 2012
Last verified: July 2012

The purpose of this study is to collect samples to evaluate the ProGRP and NSE assays independently as aids for monitoring the course of disease and therapy in subjects diagnosed with SCLC.

Small Cell Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell

Resource links provided by NLM:

Further study details as provided by Fujirebio Diagnostics, Inc.:

Biospecimen Retention:   Samples Without DNA

Collection of whole blood and urine.

Enrollment: 4
Study Start Date: May 2011
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Small cell lung cancer patients undergoing treatment.


Inclusion Criteria:

  • Age ≥ 18
  • Confirmed diagnosis of SCLC or mixed SCLC/non-SCLC per histopathology results
  • Scheduled to undergo first-, second- or third-line treatment for SCLC, including chemotherapy, chemotherapy + radiation therapy, or combined concurrent chemoradiotherapy.
  • Able to understand and willing to provide Informed Consent

Exclusion Criteria:

  • No diagnosis of SCLC
  • Not scheduled to undergo treatment for the diagnosis of SCLC
  • Unable to provide Informed Consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01591512

United States, Michigan
Kelly Family Medical Center, PC
Eastpointe, Michigan, United States, 48021
United States, Missouri
St.Louis Cancer Care, LLP
Bridgeton, Missouri, United States, 63044
Heartland Regional Medical Center
St. Joseph, Missouri, United States, 64506
Hematology Oncology Consultants, Inc.
St. Louis, Missouri, United States, 63136
Sponsors and Collaborators
Fujirebio Diagnostics, Inc.
Medical Research Networx LLC
  More Information

No publications provided

Responsible Party: Fujirebio Diagnostics, Inc. Identifier: NCT01591512     History of Changes
Other Study ID Numbers: FDI-36
Study First Received: May 2, 2012
Last Updated: July 12, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Fujirebio Diagnostics, Inc.:
Small Cell Lung Cancer
Lung Cancer
Subjects diagnosed with SCLC who will undergo treatment

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on March 01, 2015